Edition:
United States

Threshold Pharmaceuticals Inc (THLD.O)

THLD.O on Consolidated Issue listed on NASDAQ Capital Market

0.48USD
2 Dec 2016
Change (% chg)

-- (--)
Prev Close
$0.48
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,824,557
52-wk High
$3.78
52-wk Low
$0.21

Latest Key Developments (Source: Significant Developments)

Threshold Pharmaceuticals says to cut about a quarter of its workforce - SEC Filing
Thursday, 29 Sep 2016 05:38pm EDT 

Threshold Pharmaceuticals Inc: Says implementing a workforce reduction constituting approximately a quarter of the company's workforce - SEC Filing . As a result of the workforce reduction, co estimates to record in Q4 a one-time severance-related charge about $0.9 million . Says notified employees affected by the workforce reduction on September 29, 2016 . Says expects to complete the workforce reduction by October 7, 2016 . Threshold pharmaceuticals inc says on September 29, Stewart Kroll, COO, notified that his position would be eliminated as part of workforce reduction .Undertaking workforce reduction to reduce expenses, preserve capital while focusing efforts on studies of Evofosfamide.  Full Article

Threshold Pharmaceuticals Q2 loss per share $0.10
Monday, 1 Aug 2016 08:00am EDT 

Threshold Pharmaceuticals Inc : Q2 revenue $110 million . Threshold Pharmaceuticals reports second quarter financial results . Qtrly loss per share $0.10 .Q2 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S.  Full Article

Threshold Pharmaceuticals Inc announces workforce reduction
Friday, 18 Dec 2015 04:17pm EST 

Threshold Pharmaceuticals Inc:Announces workforce reduction.Says will reduce its workforce by approximately two-thirds, resulting in between 20-25 remaining employees.Anticipates one-time severance-related charge associated with workforce reduction to be about $2.6 million.Says the majority of the charges will be paid by the end of the first quarter of 2016.Sees one-time severance-related charge associated with workforce reduction to be about $2.6 million.Enacting reduction in workforce as a result of outcomes from two phase 3 trials of evofosfamide.Says Threshold has a global license and co-development agreement for evofosfamide with Merck KGaA.  Full Article

Threshold Pharmaceuticals Inc - Merck KGaA, Threshold drug fails in late-stage cancer trials - Reuters
Sunday, 6 Dec 2015 10:11pm EST 

Threshold Pharmaceuticals Inc:Merck KGaA MRCG.DE and development partner Threshold Pharmaceuticals THLD.O said their experimental cancer drug evofosfamide failed to extend lives in two late-stage clinical studies, a major setback for both firms - RTRS.Evofosfamide did not meet the main goal of improving survival in patients suffering from advanced pancreatic cancer and advanced soft tissue sarcoma, prompting the two companies to give up exploring the drug's use against these cancer forms. - RTRS.Merck said on Monday it would focus efforts on more promising candidates in its drug pipeline and would soon decide about evofosfamide's overall future - RTRS.The new disappointment leaves CEO-designate Stefan Oschmann, a pharmaceuticals expert, with a narrow drug development pipeline that rests mainly on cancer immune therapy avelumab, jointly developed with Pfizer - RTRS.  Full Article

Threshold Pharmaceuticals Inc enters into definitive co-promotion agreement for evofosfamide with Merck KGaA, Darmstadt, Germany
Wednesday, 18 Nov 2015 07:00am EST 

Threshold Pharmaceuticals Inc:Enters into definitive co-promotion agreement for evofosfamide with Merck KGaA, Darmstadt, Germany.Says may co-promote evofosfamide in the U.S. subject to FDA approval of evofosfamide.Development milestone payment, royalty payment portions of the license and co-commercialization agreement remain the same.Threshold expects to announce top-line data from evofosfamide phase 3 clinical trials around the end of 2015.  Full Article

Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial of Tarloxotinib Bromide
Thursday, 27 Aug 2015 07:00am EDT 

Threshold Pharmaceuticals Inc:Announces that the company has initiated a Phase 2 clinical trial of tarloxotinib bromide, or 'tarloxotinib' (TH-4000), for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS).  Full Article

Threshold Pharmaceuticals Inc announces pricing of $30 mln offering of common stock and warrants
Thursday, 12 Feb 2015 06:00am EST 

Threshold Pharmaceuticals Inc:Says pricing of an underwritten offering of 8,300,000 shares of its common stock together with accompanying warrants to purchase an aggregate of 8,300,000 shares of common stock.Combined offering price of each share of common stock and accompanying warrant was $3.62.Says net proceeds to Threshold from this offering are expected to be about $28.2 mln, after deducting underwriting discounts and commissions and estimated offering expenses payable by company.Expects to use net proceeds from this offering for working capital and general corporate purposes, including research and development expenses, general and administrative expenses and manufacturing expenses.Jefferies LLC is acting as sole book-running manager for the offering. H.C. Wainwright & Co., LLC. is acting as lead manager for offering.Offering is expected to close on or about Feb 18 subject to satisfaction of customary closing conditions.  Full Article